Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial

A Chéret (1) , G Nembot , A Mélard , C Lascoux , L Slama , P Miailhes , P Yeni , S Abel , V Avettand-Fenoel , A Venet , Ml Chaix , Jm Molina , C Katlama , C Goujard , C Tamalet , F Raffi , A Lafeuillade , J Reynes , I Ravaux , B Hoën , Jf Delfraissy , L Meyer , C Rouzioux , Optiprim Anrs Study Group

1 EA 7327 - Infection à VIH, réservoirs, diversité génétique et résistance aux antirétroviraux (ARV)

Domaines: Sciences du Vivant [q-bio]

A Chéret, G Nembot, A Mélard, C Lascoux, L Slama, et al.. Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial. The Lancet Infectious Diseases, 2015. ⟨hal-01968121⟩